A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC).
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2019
Price : $35 *
At a glance
- Drugs Timolumab (Primary)
- Indications Primary sclerosing cholangitis
- Focus Proof of concept; Therapeutic Use
- Acronyms BUTEO
- 30 Apr 2019 Status changed from active, no longer recruiting to completed.
- 12 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2018 Biomarkers information updated